GOAL: A Collaborative Approach to Next Generation Sequencing in Oncology and Beyond

<!doctype html><html lang="en"><head> <meta charset="utf-8"> <title>GOAL: A Collaborative Approach to Next Generation Sequencing in Oncology and Beyond</title> <link rel="shortcut icon" href="https://oxfordglobal.com/hubfs/OXFORD_GLOBAL-LOGO_SYMBOL.jpg"> <meta name="description" content="GOAL was established to drive the advancement of cutting-edge genomic testing by academic and non-academic laboratories."> <meta name="viewport" content="width=device-width, initial-scale=1"> <meta property="og:description" content="GOAL was established to drive the advancement of cutting-edge genomic testing by academic and non-academic laboratories."> <meta property="og:title" content="GOAL: A Collaborative Approach to Next Generation Sequencing in Oncology and Beyond"> <meta name="twitter:description" content="GOAL was established to drive the advancement of cutting-edge genomic testing by academic and non-academic laboratories."> <meta name="twitter:title" content="GOAL: A Collaborative Approach to Next Generation Sequencing in Oncology and Beyond"> <style> a.cta_button{-moz-box-sizing:content-box !important;-webkit-box-sizing:content-box !important;box-sizing:content-box !important;vertical-align:middle}.hs-breadcrumb-menu{list-style-type:none;margin:0px 0px 0px 0px;padding:0px 0px 0px 0px}.hs-breadcrumb-menu-item{float:left;padding:10px 0px 10px 10px}.hs-breadcrumb-menu-divider:before{content:'›';padding-left:10px}.hs-featured-image-link{border:0}.hs-featured-image{float:right;margin:0 0 20px 20px;max-width:50%}@media (max-width: 568px){.hs-featured-image{float:none;margin:0;width:100%;max-width:100%}}.hs-screen-reader-text{clip:rect(1px, 1px, 1px, 1px);height:1px;overflow:hidden;position:absolute !important;width:1px} </style> <link rel="stylesheet" href="https://oxfordglobal.com/hs-fs/hub/8696823/hub_generated/template_assets/135726131582/1732113079147/git/og-stage/css/main.min.css"> <link rel="stylesheet" href="https://cdn.oxfordglobal.com/fontawesome/6.5.1/css/fontawesome.min.css"> <link rel="stylesheet" href="https://cdn.oxfordglobal.com/fontawesome/6.5.1/css/brands.min.css"> <link rel="stylesheet" href="https://cdn.oxfordglobal.com/fontawesome/6.5.1/css/solid.min.css">  <style id="hs_editor_style" type="text/css"> #hs_cos_wrapper_module_17019620504109 { display: block !important; margin-bottom: 0px !important } </style>  <script> var _hsp = window._hsp = window._hsp || []; window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} var useGoogleConsentModeV2 = true; var waitForUpdateMillis = 1000; if (!window._hsGoogleConsentRunOnce) { window._hsGoogleConsentRunOnce = true; gtag('consent', 'default', { 'ad_storage': 'denied', 'analytics_storage': 'denied', 'ad_user_data': 'denied', 'ad_personalization': 'denied', 'wait_for_update': waitForUpdateMillis }); if (useGoogleConsentModeV2) { _hsp.push(['useGoogleConsentModeV2']) } else { _hsp.push(['addPrivacyConsentListener', function(consent){ var hasAnalyticsConsent = consent && (consent.allowed || (consent.categories && consent.categories.analytics)); var hasAdsConsent = consent && (consent.allowed || (consent.categories && consent.categories.advertisement)); gtag('consent', 'update', { 'ad_storage': hasAdsConsent ? 'granted' : 'denied', 'analytics_storage': hasAnalyticsConsent ? 'granted' : 'denied', 'ad_user_data': hasAdsConsent ? 'granted' : 'denied', 'ad_personalization': hasAdsConsent ? 'granted' : 'denied' }); }]); } } gtag('js', new Date()); gtag('set', 'developer_id.dZTQ1Zm', true); gtag('config', 'G-43QK8SYTST'); </script> <script async src="https://www.googletagmanager.com/gtag/js?id=G-43QK8SYTST"></script>  <link rel="canonical" href="https://oxfordglobal.com/biomarkers/resources/goal-a-collaborative-approach-to-next-generation-sequencing-in-oncology-and-beyond"> <meta property="og:image" content="https://oxfordglobal.com/hubfs/Website/Images/Resources/Biomarkers/GOAL-Next-Gen-Sequencing.jpg"> <meta name="twitter:image" content="https://oxfordglobal.com/hubfs/Website/Images/Resources/Biomarkers/GOAL-Next-Gen-Sequencing.jpg"> <meta property="og:url" content="https://oxfordglobal.com/biomarkers/resources/goal-a-collaborative-approach-to-next-generation-sequencing-in-oncology-and-beyond"> <meta name="twitter:card" content="summary"> <meta http-equiv="content-language" content="en"> <meta name="generator" content="HubSpot"></head> <body class="biomarkers"> <div class="body-wrapper hs-content-id-148772129196 hs-site-page page "> <div data-global-resource-path="git/og-stage/templates/partials/header.html"> <header class="website-header "> <div class="navbar"> <div class="navbar-brands"> <a href="/biomarkers" class="logo-link current-brand"> <img src="https://oxfordglobal.com/hubfs/Website/Logos/Brand%20Logos/Biomarkers%20Brand%20Logo.svg" class="logo-image"> <i class="dropdown fa-solid fa-chevron-down"></i> </a> <div class="brands"> <div class="intro"> <h2> Explore our brands </h2> <div class="desc"> Our brands bring together the industry's most influential leaders and scientific experts, inspiring thought-provoking and insightful content that offers a unique perspective on R&D trends and challenges. </div> </div> <div class="items"> <div class="item primary-brand"> <a href="/" class="logo-link"><img src="https://oxfordglobal.com/hubfs/logo.jpg" class="logo-image"></a> </div> <div class="item"> <a href="/precision-medicine" class="logo-link"><img src="https://oxfordglobal.com/hubfs/Website/Logos/Brand%20Logos/Precision%20Medicine.svg" class="logo-image"></a> </div> <div class="item"> <a href="/discovery-development" class="logo-link"><img src="https://oxfordglobal.com/hubfs/Website/Logos/Brand%20Logos/Discovery%20%26%20Development.svg" class="logo-image"></a> </div> <div class="item"> <a href="/nextgen-biomed" class="logo-link"><img src="https://oxfordglobal.com/hubfs/Website/Logos/Brand%20Logos/NextGen%20Biomed.svg" class="logo-image"></a> </div> </div> </div> </div> <div class="flex flex-align-center navbar-nav"> <a href="#" class="navbar-nav-toggle"> <div class="toggle-icons"> <i class="fa-solid fa-bars toggle-open"></i> <i class="fa-solid fa-xmark toggle-close"></i> </div> </a> <ul class="navbar-nav-items"> <li class="navbar-nav-item"> <a href="#" class="navbar-nav-item-link">Events <i class="fa-solid fa-chevron-down"></i></a> <div class="navbar-subnav"> <div class="subnav-graphics"> <img src="https://oxfordglobal.com/hubfs/Website/Images/Header%20Events.jpg" class="subnav-image"> </div> <div class="subnav-items"> <div class="subnav-item flex-3 divider g-20"> <div class="subnav-item-content bottom-mp-fix"> <h3> In-Person & Online Events </h3> <p>Pivotal moments where high-level industry experts and thought leaders come together for focused knowledge sharing and unparalleled networking opportunities.</p> </div> <div class="subnav-item"> <div class="event-pills"> </div> </div> </div> <div class="subnav-item flex-2"> <div class="subnav-item-content bottom-mp-fix"> <h3> Online Activities </h3> <p>Our Monthly Science Exchanges and Webinars keep you connected to the conversation.</p> </div> <div class="online-activities-list flex flex-column g-10"> </div> <div class="subnav-item-content-more"> <a href="/biomarkers/online" class="subnav-item-content-more-link"><i class="fa-solid fa-circle-chevron-right"></i> All Online Activities</a> </div> </div> </div> </div> </li> <li class="navbar-nav-item"> <a href="#" class="navbar-nav-item-link">Community <i class="fa-solid fa-chevron-down"></i></a> <div class="navbar-subnav"> <div class="subnav-graphics"> <img src="https://oxfordglobal.com/hubfs/Website/Images/Header%20Community.jpg" class="subnav-image"> </div> <div class="subnav-items"> <div class="subnav-item flex flex-1 divider"> <div class="subnav-item-content bottom-mp-fix"> <h3> Speakers </h3> <p>Attracting leading experts & the brightest minds in the industry to educate, inform and excite our attendees.</p> </div> <div class="subnav-item-content-more"> <a href="/biomarkers/speakers" class="subnav-item-content-more-link"><i class="fa-solid fa-circle-chevron-right"></i> More Info</a> </div> </div> <div class="subnav-item flex flex-1 divider"> <div class="subnav-item-content bottom-mp-fix"> <h3> Sponsors </h3> <p>Our range of sponsorship opportunities are highly effective in enabling market immersion and visibility, with direct access to clients and potential customers.</p> </div> <div class="subnav-item-content-more"> <a href="/biomarkers/sponsors" class="subnav-item-content-more-link"><i class="fa-solid fa-circle-chevron-right"></i> More Info</a> </div> </div> <div class="subnav-item flex flex-1 "> <div class="subnav-item-content bottom-mp-fix"> <h3> Media Partners </h3> <p>We work with leading journal publications on reciprocal marketing arrangements.</p> </div> <div class="subnav-item-content-more"> <a href="/biomarkers/media-partners" class="subnav-item-content-more-link"><i class="fa-solid fa-circle-chevron-right"></i> More Info</a> </div> </div> </div> </div> </li> <li class="navbar-nav-item"> <a href="#" class="navbar-nav-item-link">Services <i class="fa-solid fa-chevron-down"></i></a> <div class="navbar-subnav"> <div class="subnav-graphics"> <img src="https://oxfordglobal.com/hubfs/Website/Images/Header%20Services.jpg" class="subnav-image"> </div> <div class="subnav-items"> <div class="subnav-item flex flex-1 divider"> <div class="subnav-item-content bottom-mp-fix"> <h3> In-Person Services </h3> <p>At Oxford Global, our events are designed to connect key life science figures and innovative solution providers, accelerating scientific advancement. Our goal is to create valuable connections and an impactful experience through innovative and collaborative formats.</p> </div> <div class="subnav-item-content-more"> <a href="/biomarkers/in-person-services" class="subnav-item-content-more-link"><i class="fa-solid fa-circle-chevron-right"></i> More Info</a> </div> </div> <div class="subnav-item flex flex-1"> <div class="subnav-item-content bottom-mp-fix"> <h3> Digital Marketing Services </h3> <p>Oxford Global’s products offer a powerful channel to associate your brand with the latest advancements within the industry whilst educating and influencing the industry throughout their buying process.</p> </div> <div class="subnav-item-content-more"> <a href="/biomarkers/digital-marketing-services" class="subnav-item-content-more-link"><i class="fa-solid fa-circle-chevron-right"></i> More Info</a> </div> </div> </div> </div> </li> <li class="navbar-nav-item"> <a href="#" class="navbar-nav-item-link">Resources <i class="fa-solid fa-chevron-down"></i></a> <div class="navbar-subnav"> <div class="subnav-graphics"> <img src="https://oxfordglobal.com/hubfs/Website/Images/Header%20Resources.jpg" class="subnav-image"> </div> <div class="subnav-items"> <div class="subnav-item flex-2 divider"> <div class="subnav-item-content bottom-mp-fix"> <h3> Browse All Resources </h3> <p>The latest in biomarkers research, from development and diagnostics to precision medicine.</p> </div> <div class="subnav-item-content-more"> <a href="/biomarkers/resources" class="subnav-item-content-more-link"><i class="fa-solid fa-circle-chevron-right"></i> All Biomarkers Resources</a> </div> </div> <div class="subnav-item flex-4 divider"> <div class="subnav-item-content bottom-mp-fix"> <h3> Latest Resources </h3> <div class="resources"> <div class="resource"> <div class="resource-cover"> <a href="/biomarkers/resources/imaging-starts-using-brand-new-radiotracer-from-nuclidium" class="resource-cover-link"> <img src="https://oxfordglobal.com/hubfs/Website/Images/Resources/Biomarkers/Imaging%20Starts%20Using%20Brand%20New%20Radiotracer%20from%20Nuclidium.jpg" class="resource-cover-image"> </a> </div> <div class="resource-content"> <h3 class="resource-heading"> <a href="/biomarkers/resources/imaging-starts-using-brand-new-radiotracer-from-nuclidium">Imaging Starts Using Brand New Radiotracer from Nuclidium</a> </h3> <div class="resource-abstract"> <span class="resource-date">21/10/24 - </span> The radiotracer is the first part of Nuclidium’s proposed ‘theranostic pipeline’ which aims to diagnose, stage, and then treat prostate cancer. </div> </div> </div> <div class="top-divider"></div> <div class="resource"> <div class="other-resources"><a href="/biomarkers/resources/ghr-foundation-commits-15m-to-c2n-diagnostics-for-tau-tangle-pathology-test-for-diagnosing-staging-alzheimers-disease">01/10/24 - GHR Foundation Commits $15m to C2N Diagnostics for Tau Tangle Pathology Test for Diagnosing, Staging Alzheimer’s Disease</a></div> </div> <div class="top-divider"></div> <div class="resource"> <div class="other-resources"><a href="/biomarkers/resources/study-analyses-predictive-biomarkers-for-covid-19-icu-patient-mortality">06/09/24 - Study Analyses Predictive Biomarkers for COVID-19 ICU Patient Mortality</a></div> </div> </div> </div> </div> </div> </div> </li> <li class="navbar-nav-item show-sm hide-md hide-lg hide-xl"> <a href="javascript:postMessage({type:'HS_DISPLAY_CALL_TO_ACTION',id:130207947529});" class="navbar-nav-item-link">Contact</a> </li> <li class="navbar-nav-item show-sm hide-md hide-lg hide-xl"> <a href="#" class="navbar-nav-item-link">Our Brands <i class="fa-solid fa-chevron-down"></i></a> <div class="navbar-subnav"> <div class="subnav-items"> <h2> Explore our brands </h2> <div class="desc"> Our brands bring together the industry's most influential leaders and scientific experts, inspiring thought-provoking and insightful content that offers a unique perspective on R&D trends and challenges. </div> <div class="subnav-item"> <div class="subnav-item-content"> <a href="/">Oxford Global</a> </div> </div> <div class="subnav-item"> <div class="subnav-item-content"> <a href="/precision-medicine">Precision Medicine</a> </div> </div> <div class="subnav-item"> <div class="subnav-item-content"> <a href="/discovery-development">Discovery & Development</a> </div> </div> <div class="subnav-item"> <div class="subnav-item-content"> <a href="/nextgen-biomed">NextGen Biomed</a> </div> </div> </div> </div> </li> </ul> </div> <div class="flex flex-align-center hide-sm show-md show-lg show-xl"> <a href="javascript:postMessage({type:'HS_DISPLAY_CALL_TO_ACTION',id:130207947529});" class="navbar-button">Contact</a> </div> </div> </header></div> <main id="main-content"> <div class="resource-single"> <div class="header bg-primary-light"> <div class="container-wrapper"> <div class="wide-container header-container"> <div class="header-content flex-1"> <div class="heading-smallcaps"> Biomarker Discovery & Development | Industry Spotlights & Insight Articles </div> <h1 class="heading"> GOAL: A Collaborative Approach to Next Generation Sequencing in Oncology and Beyond </h1> <div class="byline"> 30 July 2022 </div> <div class="abstract"> The Genomics Organisation for Academic Laboratories – known also to the world as GOAL – is a collaborative project set up by a group of academic centres across the United States to facilitate affordable next generation sequencing. The long-term target is to expand patient access to personalised genomic testing, as well as future biomarker discovery. </div> </div> <div class="header-graphic flex-1"> <img src="https://oxfordglobal.com/hubfs/Website/Images/Resources/Biomarkers/GOAL-Next-Gen-Sequencing.jpg" class="header-graphic-image"> </div> </div> </div> </div> <div class="container-wrapper"> <div class="wide-container"> <div class="content"> <div class="content-body text-gap"> <p></p> <p>Presented by <strong>Jeremy Segal</strong>, Director of Molecular and Cytogenetic Pathology at the University of Chicago</p> <p></p> <p></p> <p>Edited by <strong>Ben Norris</strong></p> <p></p> <p></p> <p>Some of the biggest scientific breakthroughs have been collaborative efforts that stand testament to the strengths of cooperative working. One such success story is the Genomics Organisation for Academic Laboratories (GOAL). GOAL was set up to circumvent some of the traditional barriers to the development of next generation sequencing (NGS) oncology diagnostics at academic medical centres in the US. As Jeremy Segal, Director of Molecular and Cytogenetic Pathology at the University of Chicago explained, collaborative working between academic centres can help to force new ground in improving access to NGS techniques.</p> <p></p> <p></p> <h2 id="h-hurdles-to-applying-ngs-in-the-clinical-space"><strong>Hurdles to Applying NGS in the Clinical Space</strong></h2> <p></p> <p></p> <p>“Trying to develop NGS in the clinical space is a challenging process,” Segal told the audience at our 2022 Biomarkers UK: In-Person event. “There’s a lot of different equipment involved – bioinformatics is a big hurdle for all of us, and producing these tests takes a long time in terms of development.” Regulatory challenges can provide a further headache in getting new tests off the ground: prior to the advent of GOAL most academic labs have traditionally worked independently rather than collaborating on NGS methods.</p> <p></p> <p></p> <p>In 2016, Segal and his team were working on a large-scale panel looking at roughly 1,200 genes from solid tumours. “We were putting it together so that it could look for mutations and a variety of genes,” he said. “To make this work, typically if you’re doing very large-scale NGS, you’re usually talking about hybrid capture sequencing.” Segal explained that this involves fragmenting a DNA sample down to make a genomic library. “If there’s a particular fragment that you want to sequence, then you have to make a hybrid capture probe pool and pull down the sequences that you want.”</p> <p></p> <p></p> <figure class="wp-block-image size-full"><img class="wp-image-30704" src="https://oxfordglobal.com/hubfs/Website/Images/Resources/Biomarkers/Hybrid-Capture-Sequencing.jpg" alt="GOAL: Methodology underpinning hybrid capture sequencing."><figcaption><strong><em>Figure 1.</em></strong><em> Methodology underpinning hybrid capture sequencing.</em></figcaption></figure> <p></p> <p></p> <p>While this might be relatively straightforward on paper, in practice implementing this approach can be much more difficult. “We would get mostly good results, but you’d find some areas that were really problematic,” Segal explained. One example he gave was CEBPA, an important gene for acute myeloid leukaemia. The initial approach involved using large numbers of probes made as part of a batch process, which ran into problems on account of the unreliability of some probes when produced at scale. It became clear a different approach was needed.</p> <p></p>  <h2><strong>Oligonucleotide Probes: Augmenting Analytical Coverage</strong> </h2>   <p>The main problem Segal’s group was having was generating adequate sequencing data for regions with high guanine-cytosine (GC) content. Efforts to improve performance of their original bulk-generated capture technology repeatedly failed. </p>   <p>“One day we started talking to a vendor from IDT, which is a company which makes oligonucleotides,” said Segal. “They said ‘no, this is a piece of cake’. We had been conditioned to think that capturing and sequencing high GC DNA was difficult to do so we were sceptical, but we were also desperate so we tried it.” The results were tremendous: with the new probes for spiking genes into their reaction, Segal and his team at the University of Chicago were able to achieve ideal sequencing coverage across all previously problematic regions, and their panel development was rescued.</p>   <ul><li><a href="https://oxfordglobal.com/biomarkers/resources/enabling-precision-oncology-with-tumour-profiling-solutions/" target="_blank" rel="noreferrer noopener">Tumour Profiling Solutions to Enable Precision Oncology</a> </li><li><a href="https://oxfordglobal.com/biomarkers/resources/current-status-of-omics-based-biomarkers/" target="_blank" rel="noreferrer noopener">What's the Current State of Omics-Based Biomarkers?</a></li><li><a href="https://oxfordglobal.com/biomarkers/resources/quantitative-mass-spectrometry-a-clinical-tool-for-biomarker-discovery-and-qualification/" target="_blank" rel="noreferrer noopener">Quantitative Mass Spectrometry: a Clinical Tool for Biomarker Discovery and Qualification</a></li></ul>   <p></p>   <p>It turned out that the root of the problem was not inherent difficulty in capture or sequencing of high GC DNA, but in the proper manufacturing of high GC capture probes. By synthesising probes individually and performing quality control for each probe, IDT was able to generate far better results.</p>   <p>With the success of this initial pilot, the question of purchasing the entire panel through this vendor was then raised. The manufacturer proposed a very reasonable deal, although this still came to roughly USD $300,000-$500,000 in purchase. “Usually, we’d be paying USD $40,000 per 1,000 samples,” continued Segal. “But then we asked what we’d actually get if we paid this larger amount.” It transpired that the investment would be enough to test 30 million samples, which was a significant return. “For us that’s ten thousand years of tumour sequencing,” said Segal. “So we started thinking, maybe we should try to share this with somebody and buy this as a group.”</p>   <h2><strong>Shot on GOAL: Collaborative Purchases for Improved NGS Access</strong></h2>   <p>Segal reached out to long-time colleague Dara Aisner from the University of Colorado regarding a collaborative purchase. They had hoped to get three other organisations interested, but they were unprepared for the response they received. “We were really overwhelmed when 15 labs were interested in doing this,” said Segal. While the collective interest of different organisations made the purchase incredibly feasible, it also posed new complications. “With 17 academic centres, there were big content decisions to think about,” Segal continued. “There were a total of 2,640 genes that people were interested in, but over half of them were genes that only one centre cared about. So what do we do?”</p>   <p>In the end, the group decided to buy everything. “We came up with the idea of doing this in a modular format, which allows each site to formulate their own panel or a variety of different panels,” said Segal. “IDT was a really nice partner for this, because you’re talking about buying 95,109 probes divided into 2,670 pools.” There were concerns that the purchase would go awry, but the panel was a success, explained Segal. “We reformulated our panel to about 1,000 genes, and compared with our original panel we had a really nice comparison of all of our variant findings in varying frequencies. So we didn’t embarrass ourselves by wasting everyone’s money and we could show our faces in public. It was great.”</p>   <h2><strong>GOAL, Academic Partnerships, and Future Aspirations</strong></h2>   <p>Now, 29 academic centres across the United States have access to these probes and work with them every day for clinical services or the development of their operations. “Our expectation was that people would go back to working independently after everyone got the probes, but that’s not what happened,” said Segal. Researchers started asking for advice on using the probes and sequencing methods, with the overall result that research between academic centres became much more cooperative.</p>   <p><strong><em>“If we’re successful overall, we’ll have an ability to help expand patient access to personalised genomic testing.”</em></strong></p>   <p>Eventually, it was decided to turn this partnership into a functional organisation – GOAL – with a mission of driving the advancement of cutting-edge genomic testing, specifically by academic and non-academic laboratories. In 2020, Segal and Aisner partnered with the Association of Pathology Chairs (APC) to create a formal non-profit organisation with bylaws and a Board of Managers, and began the process of formalising legal master agreements with the participating institutions. </p>   <p>GOAL is now working on a number of initiatives designed to accelerate testing, reduce barriers and maximize quality across the network. For example, a network-wide concordance is under way to assess lab performance and investigate the potential benefits of implementing a cloud-based consensus bioinformatics pipeline.  The group is also laying the groundwork for large-scale sharing of genetic variants and interpretations to assist with review and curation of rare and novel genetic variants in order to enable more rapid scale-up of future sequencing panels.</p>   <p>“If we’re successful overall, we’ll have an ability to help expand patient access to personalised genomic testing,” added Segal. “We’ll get more biomarkers installed in more places, and we can actually help with future biomarker discovery as well.”</p>   <p><em>Want to learn more about the latest advances in biomarker discovery and sequencing? </em><a href="https://oxfordglobal.com/biomarkers/" target="_blank" rel="noreferrer noopener"><em>Head over to our Biomarkers portal</em></a><em> for insights from the industry's best and brightest. If you'd like to register your interest in our upcoming Biomarkers US: In-Person conference, </em><a href="https://oxfordglobal.com/biomarkers-series-us/" target="_blank" rel="noreferrer noopener"><em>visit our event website</em></a><em>.</em><br><br></p>  <div class="content-body-footer"> <div class="author-info text-no-gap"> <div class="author-about"> <h3> Speaker Biographies </h3> <p>Jeremy Segal, MD, PhD is the director of Molecular and Cytogenetic Pathology and Associate Professor of Pathology at The University of Chicago.Â  He completed his MD and PhD at Weill Cornell and Rockefeller University in New York City and Molecular Genetic Pathology fellowship at University of Pennsylvania prior to joining UChicago in 2013.Â  At UChicago, Dr. Segal is focused on the clinical development and implementation of advanced genomic testing methodologies to help diagnose and manage patients with solid tumors and hematological malignancies.Â  He is also Co-Founder of the Genomics Organization for Academic Laboratories (GOAL), a consortium effort dedicated to the advancement of genomic testing at academic and non-profit laboratories.</p> </div> </div> </div> </div> <div class="content-sidebar"> <div class="related-articles"> <h3 class="center">Related Resources</h3> <div class="article"> <a href="/precision-medicine/resources/sponsored/webinar/sapient/a-new-golden-age-for-target-identification"> <div class="cover-graphic"> <img src="https://oxfordglobal.com/hubfs/Website/Images/Resources/Omics/Sapient%20Webinar%20Website%20Featured%20Image.jpg" class="cover-graphic-image"> </div> </a><div class="content"><a href="/precision-medicine/resources/sponsored/webinar/sapient/a-new-golden-age-for-target-identification"> <h4> A New Golden Age for Target Identification: Accessing the Novel Druggable Space with Discovery Proteomics </h4> <div class="abstract"> On-demand webinar presented by Mo Jain, MD, PhD, Founder and CEO, Sapient and Jonathan Usuka, PhD, MBA Chief Business Officer, Sapient </div> <div class="read-more"> <a href="/precision-medicine/resources/sponsored/webinar/sapient/a-new-golden-age-for-target-identification" class="read-more-link">Read More</a> </div></a> </div> </div> <div class="article"> <a href="/biomarkers/resources/real-world-data-analytics-in-biomarkers"> <div class="cover-graphic"> <img src="https://oxfordglobal.com/hubfs/Website/Images/Resources/Biomarkers/Real%20World%20Data%20Analytics%20in%20Biomarker%20Discovery.jpg" class="cover-graphic-image"> </div> </a><div class="content"><a href="/biomarkers/resources/real-world-data-analytics-in-biomarkers"> <h4> The Power of Real-World Data Analytics in Biomarker Discovery: A Game-Changer in Medical Research </h4> <div class="abstract"> Biomarker discovery in medical research traditionally relied on controlled trials. Now, Real-World Data Analytics offers a transformative approach, analyzing real-world patient data to identify new biomarkers and improve patient care. </div> <div class="read-more"> <a href="/biomarkers/resources/real-world-data-analytics-in-biomarkers" class="read-more-link">Read More</a> </div></a> </div> </div> <div class="article"> <a href="/biomarkers/resources/post-event-proceedings-biomarkers-2023"> <div class="cover-graphic"> <img src="https://oxfordglobal.com/hubfs/Website/Images/Resources/Biomarkers/Biomarkers%20for%20Clinical%20Development%20Content%20Thumb.jpg" class="cover-graphic-image"> </div> </a><div class="content"><a href="/biomarkers/resources/post-event-proceedings-biomarkers-2023"> <h4> Post-Event Proceedings – Biomarkers 2023 </h4> <div class="abstract"> Concise and insightful summaries of presentations delivered by prominent thought leaders at Biomarkers 2023. </div> <div class="read-more"> <a href="/biomarkers/resources/post-event-proceedings-biomarkers-2023" class="read-more-link">Read More</a> </div></a> </div> </div> </div> </div> </div> </div> </div> </div> <div class="newsletter-cta"> <h2 class="heading">Subscribe to our newsletter</h2> <div class="message"> Sign up for our monthly Newsletter to keep up with all things Biomarkers </div> <div class="button-wrapper"> <a href="#" class="button hs-cta-trigger-button hs-cta-trigger-button-144189548681">Newsletter Sign-Up</a> </div> </div> </main> <div data-global-resource-path="git/og-stage/templates/partials/footer.html"><footer class="website-footer flex flex-column g-20"> <div class="footer-columns"> <div class="footer-column"> <a href="https://oxfordglobal.com" class="site-logo-link"> <img src="https://oxfordglobal.com/wp-content/uploads/2023/03/Oxford-Global-Logo-Stacked-Websize.png" class="site-logo"> </a> </div> <div class="footer-column"> <h3>Brands</h3> <ul> <li> <a href="/precision-medicine/">Precision Medicine</a> </li> <li> <a href="/discovery-development/">Discovery & Development</a> </li> <li> <a href="/nextgen-biomed/">NextGen Biomed</a> </li> </ul> </div> <div class="footer-column"> <h3>Services</h3> <ul> <li> <a href="https://oxfordglobal.com/in-person-services/"> In-Person Services </a> </li> <li> <a href="https://oxfordglobal.com/digital-marketing-services/"> Digital Marketing Services </a> </li> </ul> <h3>Upcoming Events</h3> <ul> <li> <a href="https://oxfordglobal.com/calendar/"> Event Calendar </a> </li> </ul> </div> <div class="footer-column"> <h3>Company</h3> <ul> <li class="elementor-icon-list-item"> <a href="https://oxfordglobal.com/about-us/"> About </a> </li> <li class="elementor-icon-list-item"> <a href="https://oxfordglobal.com/vacancies/"> Vacancies </a> </li> <li class="elementor-icon-list-item"> <a href="https://oxfordglobal.com/csr-policy/"> CSR Policy </a> </li> <li class="elementor-icon-list-item"> <a href="javascript:postMessage({type:'HS_DISPLAY_CALL_TO_ACTION',id:130207947529});"> Contact </a> </li> </ul> </div> <div class="footer-column"> <p> <a href="tel:+441865248455">+44 1865 248 455</a><br> <a href="mailto:help@oxfordglobal.com">help@oxfordglobal.com</a> </p> <p> <strong>Our UK Address:</strong><br> Godstow Court<br> Minns Business Park<br> Botley<br> Oxford, OX2 0JB </p> <p> <strong>Our US Address:</strong><br> 100 Cambridge Street<br> 14th Floor<br> Boston<br> MA 02114 </p> </div> </div> <div class="footer-bottom grid g-20"> <div class="span8 span12-sm span12-md flex flex-column g-10"> <div class="copyright"> © Oxford Global Marketing Ltd. All rights reserved. </div> <ul class="legal-links flex flex-row g-30 flex-column-sm g-sm-10"> <li><a href="https://oxfordglobal.com/legal/">Terms & Conditions</a></li> <li><a href="https://oxfordglobal.com/legal/privacy-policy/">Privacy Policy</a></li> <li><a href="https://oxfordglobal.com/legal/website-terms/">Cookies</a></li> <li><a href="https://www.wishagency.co.uk/" target="_BLANK">Digital Agency Wish</a></li> </ul> </div> <div class="span4 span12-sm span12-md flex-align-end"> <ul class="social-links flex flex-row flex-justify-end flex-justify-center-sm flex-justify-center-md g-30"> <li><a href="https://www.facebook.com/OGConferences/" target="_BLANK"><i class="fa-brands fa-square-facebook"></i></a></li> <li><a href="https://www.linkedin.com/company/oxford-global/" target="_BLANK"><i class="fa-brands fa-linkedin"></i></a></li> <li><a href="https://twitter.com/OGConferences" target="_BLANK"><i class="fa-brands fa-square-x-twitter"></i></a></li> </ul> </div> </div> </footer></div> </div> <script src="/hs/hsstatic/jquery-libs/static-1.1/jquery/jquery-1.7.1.js"></script> <script>hsjQuery = window['jQuery'];</script>  <script defer src="/hs/hsstatic/content-cwv-embed/static-1.1293/embed.js"></script> <script src="https://oxfordglobal.com/hs-fs/hub/8696823/hub_generated/template_assets/182600797781/1731148644227/git/og-stage/js/inlineSVG.min.js"></script> <script src="https://oxfordglobal.com/hs-fs/hub/8696823/hub_generated/template_assets/135724366742/1725380923802/git/og-stage/js/main.min.js"></script> <script> function getVideoId(url) { var regExp = /^.*(youtu.be\/|v\/|u\/\w\/|embed\/|watch\?v=|\&v=)([^#\&\?]*).*/; var match = url.match(regExp); if (match && match[2].length == 11) { return match[2]; } else { return false; } } function getVideoEmbed(id) { return '<iframe src="https://www.youtube.com/embed/' + id + '" title="YouTube video player" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" allowfullscreen style="aspect-ratio: 16 / 9; width: 100%;"></iframe>'; } jQuery("div.content-body .wp-block-embed__wrapper:contains('youtu')").each(function() { var yt_url = $(this).html().trim(); var yt_id = getVideoId(yt_url); var yt_embed = getVideoEmbed(yt_id); $(this).html(yt_embed); }); </script>  <script type="text/javascript"> var _hsq = _hsq || []; _hsq.push(["setContentType", "standard-page"]); _hsq.push(["setCanonicalUrl", "https:\/\/oxfordglobal.com\/biomarkers\/resources\/goal-a-collaborative-approach-to-next-generation-sequencing-in-oncology-and-beyond"]); _hsq.push(["setPageId", "hubdb-148772129196-7510174-170664398099"]); _hsq.push(["setContentMetadata", { "contentPageId": "hubdb-148772129196-7510174-170664398099", "legacyPageId": "hubdb-148772129196-7510174-170664398099", "contentFolderId": null, "contentGroupId": null, "abTestId": null, "languageVariantId": 148772129196, "languageCode": "en", }]); </script> <script type="text/javascript" id="hs-script-loader" async defer src="/hs/scriptloader/8696823.js"></script>  <script type="text/javascript"> var hsVars = { render_id: "8d9ba13b-88c4-4399-8105-7669214a9446", ticks: 1732359023484, page_id: 148772129196, dynamic_page_id: "hubdb-148772129196-7510174-170664398099", content_group_id: 0, portal_id: 8696823, app_hs_base_url: "https://app.hubspot.com", cp_hs_base_url: "https://cp.hubspot.com", language: "en", analytics_page_type: "standard-page", scp_content_type: "", analytics_page_id: "hubdb-148772129196-7510174-170664398099", category_id: 1, folder_id: 0, is_hubspot_user: false } </script> <script defer src="/hs/hsstatic/HubspotToolsMenu/static-1.354/js/index.js"></script> </body></html>

CINXE.COM

GOAL: A Collaborative Approach to Next Generation Sequencing in Oncology and Beyond